EverCommerce Stock: Is There a Path to a $12 Price Target?

"Canaccord's conviction rests on EverCommerce's cash generation, not its headline revenue numbers. The firm points to $130 million in trailing-12-month adjusted unlevered free cash flow, representing roughly 20% FCF margins as evidence that the business converts revenue into real cash at a healthy clip."

"That cash efficiency, Canaccord argues, is being underappreciated by a market fixated on the company's top-line revenue decline driven largely by divestitures rather than core business deterioration. Q4 results came in ahead of the revenue guidance midpoint, reinforcing that the core platform is stabilizing."

"The ZyraTalk acquisition and the launch of EverHealth Scribe, which saves practices an average of 8 minutes per visit, position EverCommerce to deepen its hold on more than 745,000 SMB customers, expanding revenue per customer over time."

EverCommerce trades at $10.15 with mixed analyst sentiment, ranging from Canaccord's Buy rating at $12 to Goldman Sachs' Sell at $8. Canaccord's thesis emphasizes the company's $130 million trailing-12-month adjusted unlevered free cash flow with 20% margins, arguing this cash generation capability is underappreciated by markets focused on headline revenue declines driven by divestitures rather than core business deterioration. Q4 results exceeded revenue guidance, suggesting platform stabilization. The company maintains 96% recurring revenue with 4.7% year-over-year subscription growth. Strategic initiatives including the ZyraTalk acquisition and EverHealth Scribe launch position EverCommerce to expand revenue per customer across its 745,000 small business customers through AI-powered solutions.

Read at 24/7 Wall St.